Emergent BioSolutions Inc.

EBS NYSE SEC CIK 1367644
Follow Emergent BioSolutions Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $110M −52.4% vs same quarter last year
Net income −$32.7M −163.9% vs same quarter last year
EPS, diluted −$0.64 −170.3% vs same quarter last year
Operating cash flow $100.1M +4452.2% vs same quarter last year
Revenue by quarter
$194.7M
$222.2M
$140.9M
$231.1M
$148.7M
$156.1M
$234.3M
$110M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$1B$0$1B$2BFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$742.9M$52.6M
FY24$1B−$190.6M
FY23$1B−$760.5M
FY22$1.1B−$211.6M
FY21$1.8B$219.5M
FY20$1.6B$305.8M
FY19$1.1B$54.5M
FY18$782.4M$62.7M
FY17$560.9M$82.6M
FY16$488.8M$51.8M
FY15$522.8M$62.9M
FY14$450.1M$36.7M
FY13$312.7M$31.1M
FY12$281.9M$23.5M
FY11$273.4M$23M
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−100%−50%0%50%100%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2556.1%13.5%7.1%
FY2434.7%−10.4%−18.3%
FY2330.3%−69.2%−72.5%
FY2234.3%−15.2%−18.9%
FY2150.3%19.2%12.4%
FY2059.5%28.2%19.7%
FY1960.8%10.3%4.9%
FY1858.8%11.5%8%
FY1766.5%22.2%14.7%
FY1674.2%21.6%10.6%
FY1579.4%27.1%12%
FY1477.3%19.8%8.2%
FY1380.1%13.7%10%
FY1283.7%10.6%8.3%
FY1184.6%11.7%8.4%
Free cash flowOperating cash flow minus capital expenditure
−$400M−$200M$0$200M$400MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25$156.8M
FY24$35.8M
FY23−$257.9M
FY22−$149.9M
FY21$96.1M
FY20$395M
FY19$101.1M
FY18−$30.3M
FY17$153.3M
FY16−$21.6M
FY15−$2.3M
FY14$81.6M
FY13$54.9M
FY12−$14.2M
FY11−$41.8M
Returned to shareholdersDividends paid and shares bought back
$0$50M$100M$150MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearBuybacks
FY25$24.9M
FY24$0
FY23$0
FY22$82.1M
FY21$106M
FY20$0
FY19$0
FY18$100K
FY17$33.1M
FY16$0
FY15$100K
FY14$200K
FY13$213K
FY12$5.9M
FY11$0
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Emergent BioSolutions
  • Healthcare median
−100%−50%0%50%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearEmergent BioSolutionsHealthcare median
FY257.1%−30.6%
FY24−18.3%−47%
FY23−72.5%−58%
FY22−18.9%−80.4%
FY2112.4%−71.9%
FY2019.7%−62.2%
FY194.9%−46.3%
FY188%−49.6%
FY1714.7%−45.9%
FY1610.6%−36%
FY1512%−38.4%
FY148.2%−35.5%
FY1310%−37.1%
FY128.3%−29.1%
FY118.4%−27.9%